Table 2.
Pharmacokinetic Parameters for Functional Garetosmab in Healthy Women Administered a Single Subcutaneous Dose
| Subcutaneous Garetosmab 300 mg (n = 6) | |
|---|---|
| Cmax, mg/L | |
| Mean (SD) | 31.6 (7.94) |
| Median (Min‐Max) | 33.2 (21.8‐41.4) |
| CV% | 25.1 |
| Cmax/dose, 1/L | |
| Mean (SD) | 0.105 (0.0265) |
| Median (Min‐Max) | 0.111 (0.0727‐0.138) |
| CV% | 25.1 |
| tmax, days | |
| Median (Min‐Max) | 20.9 (6.88‐21.0) |
| AUCinf, mg · day/L | |
| Mean (SD) | 1334 (376) |
| Median (Min‐Max) | 1432 (824‐1694) |
| CV% | 28.2 |
| AUCinf/dose, mg · day/L | |
| Mean (SD) | 4.45 (1.25) |
| Median (Min‐Max) | 4.77 (2.75‐5.65) |
| CV% | 28.2 |
| CL/F, mL/day | |
| Mean (SD) | 243 (79.0) |
| Median (Min‐Max) | 211 (177‐364) |
| CV% | 32.5 |
AUCinf, area under the concentration‐time curve from time zero extrapolated to infinity; CL/F, apparent clearance; Cmax, peak concentration; CV, coefficient of variation; SD, standard deviation; tmax, time to peak concentration.